FTO-Mediated Mitigation of Ferroptosis Occurs in an ACSL4-Dependent Manner in Diabetic Cardiomyopathy
Authors:
Open Access
- 18 December 2025
- journal article
- research article
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 26 (1) , 3
Abstract
Considering the global prevalence of diabetes, diabetic cardiomyopathy (DCM), as a significant diabetes complication, remains a major human challenge; while previous studies have identified ferroptosis as an important underlying mechanism, the unclear regulatory mechanisms hamper the development of therapy for DCM. In this study, we reveal that the expression of the fat mass and obesity-associated protein (FTO) is downregulated in DCM. Overexpression of FTO was found to enhance cardiac function by inhibiting ferroptosis. Mechanistically, acyl - CoA synthetase long - chain family 4 (ACSL4), a key positive mediator of ferroptosis, was identified as a direct target of FTO. The ameliorative effect of FTO was contingent upon the inhibition of ACSL4, and FTO-mediated mitigation of ferroptosis occurs in an ACSL4-dependent manner in DCM. Furthermore, we demonstrate that nicotinamide mononucleotide and sulforaphane can synergistically suppress ferroptosis by targeting distinct pathways, thereby better alleviating cardiac dysfunction. Collectively, our findings uncover an FTO - ACSL4 regulatory axis that plays a crucial role in the pathogenesis of DCM, offering valuable insights for the development of therapeutic strategies against DCM. Graphical abstract Schematic representation of FTO-mediated mitigation of ferroptosis occurs in an ACSL4-dependent manner in diabetic cardiomyopathy (DCM). FTO is downregulated in DCM, which leads to increased methylation of Acsl4 transcripts. This epigenetic modification results in elevated levels of Acsl4 mRNA and ACSL4 protein, which subsequently induces lipid peroxidation and ferroptosis. The attenuation of FTO-mediated ferroptosis is thus achieved through an ACSL4-dependent manner. Importantly, based on our previous study, NMN targeting FTO combined with SFN targeting NRF2 could synergistically inhibit ferroptosis, reducing lipid peroxidation and ferroptosis, and ultimately ameliorating DCM. DM, diabetes mellitus; FTO, fat mass and obesity-associated protein; DCM, diabetic cardiomyopathy; ACSL4, acyl-CoA synthetase long-chain family member 4; SLC7A11, solute carrier family 7 member 11; NMN, mononucleotide; SFN, sulforaphaneKeywords
Funding Information
- National Natural Science Foundation of China (82200397)
- Health Talent Project of Jilin Province (JLSWSRCZX2021)
- Natural Science Foundation of Jilin Province (YDZJ202201ZYTS013)
- 2024 Jilin University First Hospital Translational-Clinical Joint Research Fund
This publication has 35 references indexed in Scilit:
- The m6A eraser FTO suppresses ferroptosis via mediating ACSL4 in LPS-induced macrophage inflammationBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2024
- FTO alleviated ferroptosis in septic cardiomyopathy via mediating the m6A modification of BACH1Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2024
- Ferroptosis is essential for diabetic cardiomyopathy and is prevented by sulforaphane via AMPK/NRF2 pathwaysActa Pharmaceutica Sinica B, 2021
- Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillanceCell Metabolism, 2021
- Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid LeukemiaCancer Cell, 2019
- NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NRCell Metabolism, 2018
- Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and DiseaseCell, 2017
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell DeathCell, 2012
- Diabetic cardiomyopathy, causes and effectsReviews in Endocrine and Metabolic Disorders, 2010
- New type of cardiomyopathy associated with diabetic glomerulosclerosisThe American Journal of Cardiology, 1972